AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death.
On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants.
The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website.
The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS.
The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants.
The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims.
.
Sotos Class Actions
55 University Avenue, Suite 600
Toronto, ON M5J 2H7
[email protected]
1-877-294-9747 (toll free)
For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
3 hours ago
- Toronto Sun
44% of Canadian men die prematurely from largely preventable causes: Report
A new men's health report says 44% of Canadian men die prematurely from causes that are largely preventable. Photo by HANDOUT / MOVEMBER More than two in five — or 44% — of men living in Canada will die prematurely from largely preventable causes, according to a new report. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account More specifically, the Real Face of Men's Health Report — released by men's health charity Movember — finds that Canadian men are disproportionately impacted by suicide and the opioid crisis. In 2023, suicide was the fourth leading cause of premature mortality in Canadian men, with men accounting for every three in four suicides, the report said. Further, in the first half of 2024, 72% of accidental opioid toxicity deaths and 63% of accidental opioid-related poisoning hospitalizations in Canada were among men, the report said. 'For a long time, we've known about the stigmas and stereotypes that impact men's health. But now that's all really coming to a head with the alarming rates of suicide, opioid addictions, and premature deaths among Canadian men,' said Dr. John L. Oliffe, report co-author and professor, in a statement. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. 'This report is unique for the full breadth of issues and dynamics it covers, including how men's health impacts women, partners, families, communities, and the economy. We need to start paying more attention to this.' The report also explores inequities among subgroups of men, including military personnel, sexual minority men, and Indigenous men. 'It was imperative that this report specifically examine health trends among Indigenous, First Nations and Inuit populations, and while it is not surprising, it remains disheartening to see far worse health outcomes among these populations,' said Niigaan Sinclair, co-author of the report. 'As example, Inuit men have a life expectancy of just 68.8 years, more than 13 years less than non-Indigenous men. We need to seriously begin addressing such disparities.' This advertisement has not loaded yet, but your article continues below. In response, Movember is calling on Ottawa to develop a 'National Men's Health Strategy' that ensures health services, systems, and policies are responsive to the unique needs of boys and men — especially those who face systemic disadvantages. 'Men's health has been relegated to the sidelines of broader health conversations for far too long and Canada risks a true public health crisis if it does not begin to acknowledge the unique physical and mental health challenges men are experiencing,' said Michelle Terry, CEO of Movember, in a statement. Read More 'Canada can look to the progress that Australia, Ireland and the U.K. have made with government commitments to men's health, which fundamentally recognize that advocating for gender-responsive healthcare is not about prioritizing one gender over another but about addressing the unique health needs of all people.' The report's findings were drawn from HealthLumen's new economic research, analysis of national mortality trends and two sets of polls commissioned by the Movember Institute of Men's Health. One set was a nationally representative poll of 1,502 men on their experiences with primary care and the second was new polling of 1,365 people who care for men. RECOMMENDED VIDEO Toronto Blue Jays Olympics Columnists Toronto & GTA Olympics
Montreal Gazette
5 hours ago
- Montreal Gazette
‘It's destroyed a lot of lives': Families attend authorization hearings in Montreal for brainwashing class-action suit
News By Lana Ponting was only 15 years old when she was admitted to the Allan Memorial Institute in Montreal. As a rebellious teenager, it was believed the psychiatric hospital could address her 'stubbornness and disobedience.' Instead, she says, she was subjected to severe physical and mental abuse, along with psychiatric experimentation that would later become infamously known as the Montreal experiments. Now 83, frail and requiring a walker, Ponting travelled from Winnipeg to be at the Montreal courthouse Monday as authorization hearings in a class-action lawsuit over the alleged abuse began. 'It's destroyed a lot of lives,' Ponting said outside the courtroom, anger in her voice. '(I want them) to see us, to feel us. I'm alive. I will not stop. I will fight until the end.' Filed in 2019, the class-action request alleges the Canadian government funded psychiatric treatments by Dr. Donald Ewen Cameron at the institute between 1948 and 1964. The experiments were allegedly part of the CIA's MK-ULTRA program of covert mind-control. In addition to the government, the lawsuit also targets McGill University, which was affiliated to the psychiatric hospital, and Montreal's Royal Victoria Hospital. 'This is not a medical or professional malpractice case. ... This is a case of systemic abuse,' lawyer Jeff Orenstein told the court on Monday. 'When people went to the Allan Memorial, they were told they would be receiving legitimate treatment,' he added. 'Instead they were human guinea pigs.' The defendants are contesting the class-action request, partly arguing the families waited too long to file their claims according to the law. The Canadian government also contends that some families accepted $100,000 payments from the federal government in the 1990s, which then barred them from pursuing further legal action. They will plead their case on Tuesday. Orenstein, for his part, argues the victims were unable to act earlier because of the trauma and psychological pain they endured. He believes the suit could grow to include several hundred people. The lawsuit had tried to include the U.S. government as a defendant, but Quebec's Court of Appeal ruled that the U.S. cannot be sued in Canada for its alleged role in the experiments; the Supreme Court of Canada refused to review the case. Julie Tanny, the lead plaintiff in the case, said she spent years not speaking about what happened to her father, Charles, because of the stigma attached. The few times she did, she added, she was met with disbelief. Present for the hearing, Tanny said she still can't accept the way her father changed after his stay at the institute in 1957 to treat facial pain. She described the warm and engaged father she once knew as having completely 'evaporated' after his treatment. He grew distant and barely recognized his children. 'For a kid, it's very traumatizing to have that relationship go away and not really understand why,' said Tanny, 71. 'It was the beginning of a nightmare for hundreds and hundreds of families.' In court on Monday, Orenstein detailed the experiments Cameron carried out on patients, noting how they were all well-documented at the time. Rather than scientific efforts, he compared them to acts of psychological torture. He described how patients were allegedly subjected to sensory deprivation and drug-induced comas, forced to listen to repeated audio messages on loop and to undergo extensive electroshock treatment. In some cases, he said, people were reduced to a childlike state. Others left the hospital as 'robots with no human emotions.' Lisa Moore, whose mother Hélène was sent to the hospital in the early 1960s, left the courtroom in tears as the alleged abuse was described, her emotions too difficult to contain. Now 54, Moore grew up in foster care and spent decades resenting her mother for how she treated her. But hearing the extent of what she went through laid bare in court on Monday provided a new perspective. 'It wasn't her fault. They took away her ability for compassion,' said Moore, who reconciled with her mother in recent years. 'It's very overwhelming,' she added. 'I just keep imagining what it was like for her.'
Cision Canada
6 hours ago
- Cision Canada
AURORA CANNABIS CHS CLASS ACTION CERTIFIED
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death. On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants. The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website. The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS. The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants. The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims. . Sotos Class Actions 55 University Avenue, Suite 600 Toronto, ON M5J 2H7 [email protected] 1-877-294-9747 (toll free) For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
